Pharmaceutical Executive-10-22-2009

Pharmaceutical Executive

October 21, 2009

The third quarter reports are in, and Pfizer's profits are up but sales are down. The company is compensating for looming patent expirations with layoffs and restructuring; is it enough to boost sales?